Analysis: Mpox and Cholera Outbreaks Underscore Importance of Gavi’s African Vaccine Initiative – But Doubts Remain

Mpox And Cholera Outbreaks Underscore Importance Of Gavi’s African Vaccine Initiative - But Can It Ensure Equity? - Health Policy Watch Back in June, the vaccine platform, Gavi, launched the African Vaccine Manufacturing Accelerator (AVMA), together with the African Union and Africa Centres Health Policy Watch

...

African countries affected by mpox are dependent on vaccine donations from wealthy countries, while a dire global shortage of cholera vaccines has forced the World Health Organization (WHO) to advise countries to give people one dose instead of the optimal two.

Back in June, the vaccine platform, Gavi, launched the African Vaccine Manufacturing Accelerator (AVMA), together with the African Union and Africa Centres for Disease Control and Prevention (Africa CDC).

“AVMA is a financing mechanism established to make up to $1.2 billion available over 10 years, commencing with AVMA’s launch in June 2024, to accelerate the expansion of commercially viable vaccine manufacturing in Africa,” a Gavi spokesperson told Health Policy Watch.

High hopes are invested in AVMA, but the initiative has also been criticised for offering incentives that favour established international manufacturers rather nurturing than smaller, truly African manufacturers.

...